CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX), today provided in-depth analysis from COMET-1 (CRx-102 Osteoarthritis Multi-center Evaluation Trial), the Company's Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive™ (CRx-102) in subjects with symptomatic knee osteoarthritis (OA). Based on an in-depth analysis reviewed with clinical investigators and thought leaders during the American College of Rheumatology meeting in San Francisco, CombinatoRx has posted a webcast presentation of the data by Lee S. Simon, MD, Associate Clinical Professor of Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center and former Division Director of Analgesic, Anti-inflammatory & Ophthalmologic Drug Products at the FDA in the investors section of its website at www.combinatorx.com.
